Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2025
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: A randomized, double-blind, placebo-controlled Phase Ib/IIa trial
Signal Transduct Target Ther 2025;10:383 Doi: 10.1038/s41392-025-02487-2
Zhao et al. showed that CM313 was well tolerated in adult patients with SLE at doses of 2–16mg/kg and showed encouraging pharmacodynamic effects and preliminary efficacy at doses of 8 and 16 mg/kg QW. CM313 also produced dose-dependent and clinically meaningful improvements in key serological biomarkers of SLE.
October 2025
A Phase 3 trial of telitacicept for systemic lupus erythematosus
N Engl J Med 2025;393:1475-85 Doi: 10.1056/NEJMoa2414719
In this 52-week trial involving participants with active SLE who were receiving background therapy, the incidence of a clinical response was higher with telitacicept than with PBO. van Vollenhoven et al. report efficacy and safety results of a Phase 3 trial of telitacicept at a dose of 160mg weekly as compared with PBO in Chinese persons with active SLE.